MX2016016992A - Aptameros especificos de tlr-4 y usos de los mismos. - Google Patents

Aptameros especificos de tlr-4 y usos de los mismos.

Info

Publication number
MX2016016992A
MX2016016992A MX2016016992A MX2016016992A MX2016016992A MX 2016016992 A MX2016016992 A MX 2016016992A MX 2016016992 A MX2016016992 A MX 2016016992A MX 2016016992 A MX2016016992 A MX 2016016992A MX 2016016992 A MX2016016992 A MX 2016016992A
Authority
MX
Mexico
Prior art keywords
tlr
relates
aptamer
increase
aptamers specific
Prior art date
Application number
MX2016016992A
Other languages
English (en)
Other versions
MX387405B (es
Inventor
LIZASOAIN HERNÁNDEZ Ignacio
Manuel GONZÁLEZ MUÑOZ Víctor
Fernández Gómez-Chacón Gerónimo
Ángeles MORO SÁNCHEZ María
ELENA MARTÍN PALMA Mª
Moraga Yébenes Ana
Original Assignee
Aptus Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptus Biotech S L filed Critical Aptus Biotech S L
Publication of MX2016016992A publication Critical patent/MX2016016992A/es
Publication of MX387405B publication Critical patent/MX387405B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)

Abstract

La invención se relaciona con un ácido nucleico aptámero con la capacidad de unirse específicamente e inhibir TLR-4, a un complex que comprenda dicho aptámero y un grupo funcional, así como a las composiciones farmacéuticas derivadas de ellos. La invención también se relaciona con los usos y métodos para inhibir TLR-4. Finalmente, la invención también se relaciona con un aptámero para uso en la manufactura de un fármaco para el tratamiento de una patología caracterizada por un aumento en la expresión de TLR-4 y/o un aumento en la activación de TLR-4.
MX2016016992A 2014-06-24 2015-06-24 Aptámeros específicos de tlr-4 y usos de los mismos. MX387405B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430955A ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos
PCT/EP2015/064277 WO2015197706A1 (en) 2014-06-24 2015-06-24 Aptamers specific for tlr-4 and uses thereof

Publications (2)

Publication Number Publication Date
MX2016016992A true MX2016016992A (es) 2017-05-03
MX387405B MX387405B (es) 2025-03-18

Family

ID=53496661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016992A MX387405B (es) 2014-06-24 2015-06-24 Aptámeros específicos de tlr-4 y usos de los mismos.

Country Status (18)

Country Link
US (4) US10196642B2 (es)
EP (1) EP3161139B1 (es)
JP (2) JP6959738B2 (es)
KR (1) KR102454682B1 (es)
CN (2) CN106459980B (es)
AU (1) AU2015279248B2 (es)
BR (1) BR112016030172B1 (es)
CA (1) CA2953020C (es)
DK (1) DK3161139T3 (es)
ES (2) ES2555160B1 (es)
MA (1) MA40283A (es)
MX (1) MX387405B (es)
PL (1) PL3161139T3 (es)
PT (1) PT3161139T (es)
RU (1) RU2709718C9 (es)
SI (1) SI3161139T1 (es)
WO (1) WO2015197706A1 (es)
ZA (1) ZA201700363B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709776B2 (en) * 2014-04-07 2020-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing outer membrane vesicles
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3494994A1 (en) * 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020065404A2 (en) 2018-09-28 2020-04-02 Augmanity Nano Ltd Methods and compositions for selection of functional aptamers
MX2021003421A (es) 2018-09-28 2021-06-15 Nutcracker Therapeutics Inc Formulaciones de nanoparticulas lipidicas que comprenden compuestos peptidicos cationicos lipidados para el suministro de acidos nucleicos.
AU2019352635B2 (en) 2018-10-02 2024-12-19 WearOptimo Pty Ltd Actuator system
EP3860453A4 (en) 2018-10-02 2022-08-03 Wearoptimo Pty Ltd Measurement system
WO2020069568A1 (en) 2018-10-02 2020-04-09 WearOptimo Pty Ltd Treatment delivery system
WO2020230108A1 (en) * 2019-05-16 2020-11-19 Aptatargets, S.L. Treatment of ischemic stroke with aptamers targeting tlr-4
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
US20230372407A1 (en) * 2020-06-15 2023-11-23 President And Fellows Of Harvard College Methods for modulating tlr4 signaling
CN114152599B (zh) * 2021-12-01 2023-10-13 中国农业大学 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器
CN114836425A (zh) * 2022-02-25 2022-08-02 温州医科大学附属眼视光医院 检测小胶质细胞的核酸适体及应用
KR20250133725A (ko) 2023-01-05 2025-09-08 메르크 파텐트 게엠베하 허혈성 뇌졸중 및 두개강내 출혈을 치료하기 위한 ApTOLL 분자
AU2024275027A1 (en) 2023-05-22 2025-12-11 Merck Patent Gmbh New tlr-4 antagonist aptamers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
IL151047A0 (en) * 2000-02-03 2003-04-10 Res Dev Foundation Signaling aptamers that transduce molecular recognition to a differential signal
CN101227922A (zh) * 2005-05-06 2008-07-23 斯克里普斯研究学院 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
EP1895842A4 (en) * 2005-06-17 2009-06-03 Univ Rochester METHOD AND COMPOSITIONS FOR EXPANDING THE IMMUNE MEMORY BY BLOCKING INTRA-HEPATIBLE ACTIVATED T-CELL ERASURE
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
WO2008076804A2 (en) * 2006-12-13 2008-06-26 Case Western Reserve University Method of treating intrauterine inflammation
US20100111936A1 (en) * 2008-11-04 2010-05-06 Idera Pharmaceuticals, Inc. Modulation of Toll-Like Receptor 4 Expression by Antisense Oligonucleotides
WO2010060030A1 (en) * 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same
EP2681315B1 (en) * 2011-03-03 2017-05-03 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
CN103492572A (zh) * 2011-03-03 2014-01-01 夸克医药公司 用于治疗肺疾病和损伤的组合物和方法
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos

Also Published As

Publication number Publication date
US20230279402A1 (en) 2023-09-07
BR112016030172B1 (pt) 2022-11-01
KR102454682B1 (ko) 2022-10-13
ZA201700363B (en) 2018-11-28
SI3161139T1 (sl) 2020-12-31
US20190211334A1 (en) 2019-07-11
CN112111495A (zh) 2020-12-22
ES2555160B1 (es) 2016-10-25
WO2015197706A1 (en) 2015-12-30
AU2015279248A1 (en) 2017-01-12
US20210130830A1 (en) 2021-05-06
BR112016030172A2 (pt) 2017-11-14
CN106459980A (zh) 2017-02-22
JP2017527260A (ja) 2017-09-21
US11591603B2 (en) 2023-02-28
EP3161139A1 (en) 2017-05-03
PT3161139T (pt) 2020-10-23
JP2020127422A (ja) 2020-08-27
ES2825106T3 (es) 2021-05-14
MA40283A (fr) 2017-05-03
RU2709718C2 (ru) 2019-12-19
EP3161139B1 (en) 2020-07-22
RU2016152094A (ru) 2018-07-26
CA2953020C (en) 2023-01-10
US10196642B2 (en) 2019-02-05
CA2953020A1 (en) 2015-12-30
JP6959738B2 (ja) 2021-11-05
CN106459980B (zh) 2020-11-03
PL3161139T3 (pl) 2021-01-11
MX387405B (es) 2025-03-18
ES2555160A1 (es) 2015-12-29
KR20170021298A (ko) 2017-02-27
US20170130227A1 (en) 2017-05-11
RU2016152094A3 (es) 2019-01-29
RU2709718C9 (ru) 2020-02-06
AU2015279248B2 (en) 2021-03-11
DK3161139T3 (da) 2020-10-19
US10808252B2 (en) 2020-10-20

Similar Documents

Publication Publication Date Title
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
CO2017011851A2 (es) Compuestos novedosos
BR112016025427A2 (pt) processos de preparação de um inibidor de jak1 e formas do mesmo
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
CL2016000539A1 (es) Compuestos aza-piridina y usos de los mismos
CO2017001884A2 (es) Polimorfos de selinexor
CO7240361A2 (es) Composiciones de arni de serpinc1 y métodos de uso de las mismas
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
DOP2016000253A (es) Nuevos compuestos
ECSP17061751A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112017009289A2 (pt) métodos de administrar composições de amantadina
UY35747A (es) Derivados sustituidos de fenilalanina
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CR20170264A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20170185A1 (es) Composiciones farmaceuticas para tratar enfermedades infecciosas
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
UY35745A (es) Derivados sustituidos de fenilalanina
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CR20160432A (es) Inhibidores de las vías de señalización de wnt